News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
5.890
-0.340 (-5.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
September 10, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 09, 2024
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
September 09, 2024
Via
Benzinga
Key Takeaways From C4 Therapeutics Analyst Ratings
May 09, 2024
Via
Benzinga
Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
February 26, 2024
Via
Benzinga
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
September 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
September 03, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in Upcoming September Investor Conferences
August 29, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For C4 Therapeutics's Future
January 29, 2024
Via
Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) Leading the Way in Wednesday Trading Based on Percentage Gain
January 10, 2024
Via
Investor Brand Network
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
August 14, 2024
Investor Webcast Moved to Friday, September 13, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 01, 2024
CCCC stock results show that C4 Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
July 16, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
June 10, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
CCCC stock results show that C4 Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
April 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
March 05, 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 20, 2024
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 50 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns.
Via
InvestorPlace
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.